Because authorised in 2014, tucidinostat was considered as a second-line and subsequent therapy for PTCL individuals in China. Medical trials and preclinical studies in numerous hematological malignancies and stable tumors is in development. Cyclosporine is often a widely made use of immunosuppre

Identify your assortment: Identify has to be below characters Opt for a collection: Not able to load your assortment due to an error "NCI is committed to sharing information in accordance with NIH coverage. For more details on how medical trial knowledge is shared, accessibility the connecti